New Indications and Platforms for CAR-T Therapy in Lymphomas Beyond DLBCL

Overview

Journal EJHaem

Specialty Hematology

Date 2022 Jan 6

PMID 34988550

Citations 2

Authors

Madiha Iqbal

Bipin N Savani

Mehdi Hamadani

Affiliations

Soon will be listed here.

Abstract

CD19 directed chimeric antigen receptor T-cell therapy (CAR-T) represents a significant advancement for patients with relapsed/refractory large B-cell lymphoma (LBCL). Long term follow-up confirms durable remissions in nearly half of the patients, a population which was previously estimated to have a median survival of around 6 months with standard salvage therapy. This initial success of CAR-T has led to significant expansion across other lymphoma histologies resulting in the recent regulatory approval of CAR-T in mantle cell lymphoma and follicular lymphoma. Additionally, multiple novel platforms of CAR-T therapy are under development to improve efficacy and limit toxicity such dual antigen targeting, allogeneic and natural killer CAR's. In this review, we focus on the new indications of CAR-T in lymphomas beyond LBCL as well as emerging platforms of CAR-T therapy.

Citing Articles

Chimeric antigen receptor-T cell therapies: The changing landscape.

Sengsayadeth S, Dholaria B, Savani B, Oluwole O EJHaem. 2022; 3(Suppl 1):3-5.

PMID: 35844302 PMC: 9176045. DOI: 10.1002/jha2.340.

New Indications and platforms for CAR-T therapy in lymphomas beyond DLBCL.

Iqbal M, Savani B, Hamadani M EJHaem. 2022; 3(Suppl 1):11-23.

PMID: 34988550 PMC: 8725814. DOI: 10.1002/jha2.323.

References

Shah N, Johnson B, Schneider D, Zhu F, Szabo A, Keever-Taylor C . Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020; 26(10):1569-1575. DOI: 10.1038/s41591-020-1081-3. View

Ramos C, Ballard B, Zhang H, Dakhova O, Gee A, Mei Z . Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017; 127(9):3462-3471. PMC: 5669573. DOI: 10.1172/JCI94306. View

Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S . Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. Cancer Res. 2015; 75(18):3853-64. DOI: 10.1158/0008-5472.CAN-14-3321. View

Jain P, Wang M . Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019; 94(6):710-725. DOI: 10.1002/ajh.25487. View

Spiegel J, Patel S, Muffly L, Hossain N, Oak J, Baird J . CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021; 27(8):1419-1431. PMC: 8363505. DOI: 10.1038/s41591-021-01436-0. View

Melenhorst J, Leen A, Bollard C, Quigley M, Price D, Rooney C . Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010; 116(22):4700-2. PMC: 2996125. DOI: 10.1182/blood-2010-06-289991. View

Rupp L, Schumann K, Roybal K, Gate R, Ye C, Lim W . CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017; 7(1):737. PMC: 5428439. DOI: 10.1038/s41598-017-00462-8. View

Leen A, Bollard C, Mendizabal A, Shpall E, Szabolcs P, Antin J . Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013; 121(26):5113-23. PMC: 3695359. DOI: 10.1182/blood-2013-02-486324. View

Kanate A, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P . Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019; 5(5):715-722. PMC: 6988125. DOI: 10.1001/jamaoncol.2018.6278. View

10.

Guedan S, Calderon H, Posey Jr A, Maus M . Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019; 12:145-156. PMC: 6330382. DOI: 10.1016/j.omtm.2018.12.009. View

11.

Ruella M, Xu J, Barrett D, Fraietta J, Reich T, Ambrose D . Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018; 24(10):1499-1503. PMC: 6511988. DOI: 10.1038/s41591-018-0201-9. View

12.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

13.

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

14.

Eskelund C, Kolstad A, Jerkeman M, Raty R, Laurell A, Eloranta S . 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016; 175(3):410-418. DOI: 10.1111/bjh.14241. View

15.

Deng Q, Han G, Puebla-Osorio N, Ma M, Strati P, Chasen B . Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020; 26(12):1878-1887. PMC: 8446909. DOI: 10.1038/s41591-020-1061-7. View

16.

Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

17.

Daher M, Rezvani K . Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018; 51:146-153. PMC: 6140331. DOI: 10.1016/j.coi.2018.03.013. View

18.

Singh N, Perazzelli J, Grupp S, Barrett D . Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016; 8(320):320ra3. DOI: 10.1126/scitranslmed.aad5222. View

19.

Riolobos L, Hirata R, Turtle C, Wang P, Gornalusse G, Zavajlevski M . HLA engineering of human pluripotent stem cells. Mol Ther. 2013; 21(6):1232-41. PMC: 3677304. DOI: 10.1038/mt.2013.59. View

20.

Frigault M, Dietrich J, Martinez-Lage M, Leick M, Choi B, DeFilipp Z . Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019; 134(11):860-866. PMC: 7022436. DOI: 10.1182/blood.2019001694. View